Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
187
-
Total 13F shares, excl. options
-
49.6M
-
Shares change
-
+7.59M
-
Total reported value, excl. options
-
$498M
-
Value change
-
+$69.9M
-
Put/Call ratio
-
0.98
-
Number of buys
-
94
-
Number of sells
-
-65
-
Price
-
$10.05
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2022
245 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2022.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 187 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.6M shares
of 131M outstanding shares and own 37.92% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.81M shares), FMR LLC (4.89M shares), NEA Management Company, LLC (3.97M shares), MORGAN STANLEY (2.89M shares), Bellevue Group AG (2.67M shares), STATE STREET CORP (2.39M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.72M shares), VANGUARD GROUP INC (1.17M shares), GEODE CAPITAL MANAGEMENT, LLC (1.16M shares), and STIFEL FINANCIAL CORP (1.04M shares).
This table shows the top 187 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.